The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline (Q37784829)

23 August 2017

The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline (English)

1 reference

23 August 2017

0 references

4

René S Kahn

1 reference

23 August 2017

Christiaan H Vinkers

1

1 reference

23 August 2017

Naheed R Mirza

series ordinal

2

1 reference

23 August 2017

Berend Olivier

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Expert Opinion on Investigational Drugs

23 August 2017

1 reference

23 August 2017

19

1 reference

23 August 2017

10

1 reference

23 August 2017

1217-1233

1 reference

Genetic basis of schizophrenia.

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Glutamate decarboxylase(65)-immunoreactive terminals in cingulate and prefrontal cortices of schizophrenic and bipolar brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

GABA transporters as drug targets for modulation of GABAergic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Which GABAA-receptor subtypes really occur in the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Evolution of GABA(A) receptor diversity in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

GABA-based therapeutic approaches: GABAA receptor subtype functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Subunit composition, distribution and function of GABA(A) receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Extrasynaptic GABAA receptors: form, pharmacology, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

A new benzodiazepine pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Cortical inhibitory neurons and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Altered markers of tonic inhibition in the dorsolateral prefrontal cortex of subjects with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

[123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

GABAA/Benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for alpha5 subunit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Systematic study of association of four GABAergic genes: glutamic acid decarboxylase 1 gene, glutamic acid decarboxylase 2 gene, GABA(B) receptor 1 gene and GABA(A) receptor subunit beta2 gene, with schizophrenia using a universal DNA microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Association of SNPs and haplotypes in GABAA receptor beta2 gene with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

A recombination hotspot in a schizophrenia-associated region of GABRB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Mutational screening and association study of glutamate decarboxylase 1 as a candidate susceptibility gene for bipolar affective disorder and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

New insights into the role of thyroid hormone in the CNS: the microglial track

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Genetic investigation of chromosome 5q GABAA receptor subunit genes in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Association study of the gamma-aminobutyric acid type a receptor gamma2 subunit gene with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Cognitive Effects of Long-Term Benzodiazepine Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Effects of diazepam on cognitive processes in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Memory effects of benzodiazepines: memory stages and types versus binding-site subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Atypical behavioural effects of lorazepam: clues to the design of novel therapies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

GABA(A) receptor subtype selective cognition enhancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Pharmacology of the beta-carboline FG-7,142, a partial inverse agonist at the benzodiazepine allosteric site of the GABA A receptor: neurochemical, neurophysiological, and behavioral effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Bidirectional effects of beta-carbolines and benzodiazepines on cognitive processes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

An inverse agonist selective for alpha5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Identification of a Novel, Selective GABAAα5 Receptor Inverse Agonist Which Enhances Cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Reversal of ketamine-induced working memory impairments by the GABAAalpha2/3 agonist TPA023.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Long-term effects of tiagabine monotherapy on cognition and mood in adult patients with chronic partial epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Modeling cognitive endophenotypes of schizophrenia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Neuronal oscillations in cortical networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Mechanism for top-down control of working memory capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Abnormal neural oscillations and synchrony in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Cortical oscillatory activity is critical for working memory as revealed by deficits in early-onset schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Protracted developmental trajectories of GABAA receptor alpha1 and alpha2 subunit expression in primate prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

General and specific cognitive deficits in schizophrenia: Goliath defeats David?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

General and social cognition in first episode schizophrenia: identification of separable factors and prediction of functional outcome using the IntegNeuro test battery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Assessing cognitive function in clinical trials of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

The dopamine hypothesis of schizophrenia: version III--the final common pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Schizophrenia-like GABAergic gene expression deficits in cerebellar Golgi cells from rats chronically exposed to low-dose phencyclidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Dopamine innervation of a subclass of local circuit neurons in monkey prefrontal cortex: ultrastructural analysis of tyrosine hydroxylase and parvalbumin immunoreactive structures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Pathophysiologically based treatment interventions in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

The novel anxiolytic ELB139 displays selectivity to recombinant GABA(A) receptors different from diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513382

10.1517/13543784.2010.513382

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference